Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine eluted cardiovascular support

A cardiovascular and drug technology, applied in the field of balloon-expandable stents, can solve the problems of complex preparation technology and unfavorable promotion and use, and achieve the effects of promoting healing, overcoming intolerance to body fluid washout, and preventing late thrombosis

Inactive Publication Date: 2005-09-21
程树军
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] The technical problem to be solved in the present invention is to disclose a drug-eluting cardiovascular stent to overcome the subacute thrombus and long-term restenosis in the prior art and the preparation technology is relatively complicated, and harmful substances (ethyleneimine) are introduced , is not conducive to popularization and use of defects, to meet people's needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Preparation of biodegradable materials:

[0033] Weigh 70 parts of L-lactide, 5 parts of glycolide and 25 parts of ε-caprolactone in a dry polymerization bottle with a stirring bar, and use N 2Replaced 3 times, placed in an oil bath at 160°C, after melting, added a certain volume of 0.02g / ml stannous octoate chloroform solution (catalyst amount is 0.02wt% of monomer mass), removed chloroform under reduced pressure, and reacted under stirring After 5h, the polymer was dissolved with chloroform and precipitated with ethanol. The molecular weight of the obtained polymer was characterized by gel permeation chromatography (GPC), and the molecular weight was greater than 100,000.

Embodiment 2

[0035] Preparation of heparinized poly(lactic-glycolic acid-amino acids):

[0036] Weigh 0.1mol L-lactide and 0.05mol morpholine dione derivative monomer containing benzyloxy-protected glutamic acid in a dry polymerization bottle with a stirring bar, and use N 2 Replace 3 times, place in 160°C oil bath, after melting, add a certain volume of 0.02g / ml stannous octoate chloroform solution, remove chloroform under reduced pressure, react for 5h under stirring, dissolve polymer with chloroform, and precipitate with ethanol. The obtained polymer is de-benzyloxyl grouped with Pd / C catalyst and hydrogen gas bubbling for 40 to obtain poly(lactic acid-glycolic acid-glutamic acid).

[0037] Heparin contains amino groups and carboxyl groups. Dissolve poly(lactic acid-glycolic acid-aspartic acid) in a mixed solvent of tetrahydrofuran and water, dissolve heparin sodium in a small amount of water, and adjust the pH to about 4 with dilute acid. Mix the two, add an equivalent amount of dicyc...

Embodiment 3

[0039] Dissolve 0.1 gram of heparinized poly(lactic acid-glycolic acid-amino acid), 0.1 gram of anti-restenosis drug rhubarb and 0.1 gram of rapamycin (Rampamycin) in 5 ml of chloroform, and then immerse the balloon-expandable stent in the solution About 30s, take it out and blow dry for later use. The stent can overcome restenosis in the stent and prevent the formation of acute and subacute thrombus. Meanwhile, the heparin has an anti-inflammation effect, can inhibit the foreign body inflammatory reaction of the stent, and promote the healing of the wound on the inner wall of the blood vessel.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A kind of medicinal elution cardiovascular frame, comprises frame and biological degradation layer, which is made of biological degradation material that embeds the drug and covered in the frame. The characteristic is: the biological degradation material includes glycolide, L-lactide, homopolymers or one of the copolymer and the copolymer with polyfunctional group amino acid of Epsilon-caprolactone; the biological degradation layer contains the drug is a kind of macromolecule graft heparin. After the frame is implanted, the drug is deliveried to limit the endometrial hyperplasia sufficiently, and the heparin is exist continuously and steadily. It can prevent the occurrence of acute or subacute thrombus, and can promote the healing of the injury vessel wall, prevent the occurrence of late thrombus. Compare to the traditional heparin frame, it overcomes the defects like intolerance by the humor erosion and interceding poison substance in the progress of chemical binding.

Description

technical field [0001] The invention relates to a medicinal stent, in particular to a balloon-expandable stent used in cardiovascular systems, capable of releasing therapeutic drugs and promoting the healing of damaged blood vessel walls. Background technique [0002] In 1964, Dotter and Judkings (Dotter CT, Jukines MP. Tranaluminal treatmantof arteriosclerotic obstruction, 1964, 30: 654) proposed the concept of percutaneous transluminal angioplasty, and assumed that silicone rubber or plastic was used to support the blood vessel to maintain the lumen of the blood vessel. In 1987, Sigwart (Sigwart U, et al. Intravascular stents to prevent occlusion and restenosis after tranaluminal angioplasty. N Engl J Med, 1987; 316: 701) first used intravascular metal stents for coronary arteries, for Treatment of vascular occlusive disease provides a good way. [0003] An ideal stent should have the following characteristics: (1) better biocompatibility: minimal procoagulant effect, les...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61F2/06A61M29/00
Inventor 葛均波王克强刘学波王耀先赵燕超饶炬程树军
Owner 程树军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com